Shots:
- Metsera announced entering into an amended merger agreement with Pfizer to acquire Metsera for up to $86.25 per share, including $65.60 in cash and a contingent value right of up to $20.65
- Metsera’s Board of Directors noted that the U.S. Federal Trade Commission had raised potential antitrust concerns regarding Novo Nordisk’s proposed structure
- After careful evaluation, the Board determined that Novo Nordisk’s offer posed material legal and regulatory risks, including the possibility that the initial dividend may not be paid or could later be challenged, rendering Pfizer’s proposal a more secure and favorable option for Metsera and its shareholders
Ref: Metsera | Image: Metsera | Press Release
Related News: Metsera Declares Novo Nordisk’s ~$9B Acquisition Proposal a Superior Offer to Pfizer Merger Agreement
